May 2, 2026 - 05:03

Businesses are moving to take ownership of their data in order to customize artificial intelligence for their specific needs. The main challenge is finding a balance between keeping that ownership and ensuring the safe, trusted movement of high-quality data required for generating dependable insights. This was a key topic at MIT Technology Review's EmTech AI conference, where experts discussed how AI factories are unlocking new levels of scale, sustainability, and governance.
The idea of data sovereignty is becoming central to how companies approach AI. Rather than relying solely on third-party models or external data sources, organizations want to build systems that reflect their own operations and values. This shift allows them to tailor AI tools more precisely, but it also requires careful management of data flows. Without proper governance, the risk of bias or unreliable outputs increases.
Speakers at the conference emphasized that achieving scale in AI is not just about computing power. It also depends on creating trusted pipelines for data that can be audited and controlled. As companies build these internal AI factories, they are positioning themselves to compete more effectively while maintaining control over their most valuable asset: their data. The conversation highlighted that the future of AI will be shaped as much by how data is handled as by the algorithms themselves.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...